President Donald Trump announced a 100% import tariff on branded pharmaceutical drugs starting October 1, with exemptions for companies actively building manufacturing plants in the U.S. This measure aims to incentivize domestic drug production but creates significant uncertainty for thousands of small and mid-sized biotech firms reliant on imports. Generic drugs remain exempt. Industry awaits clarifications on scope and exemptions as policies evolve.